Explore the vast range of titles available.

The President of the Critical Path Institute discusses the successes to date and future challenges of helping the FDA to improve the process for developing safe, innovative drugs.

A well-defined pathway for the accelerated development and approval of targeted cancer therapies and companion diagnostics would reduce uncertainty, improve efficiency in development and provide an effective incentive for developers.

To the Editor: Ray et al. (Dec. 30 issue) 1 are to be complimented on their arguments in favor of changing the way we evaluate drugs after they have been approved for clinical use. As clinical pharmacologists, we strongly endorse their proposals for more research in this area and for a national center for the evaluation of new drugs. Independently, we arrived at similar conclusions and have proposed the creation of centers for education and research in therapeutics 2 . The concept of an independently funded center that could conduct research on drugs is not new. An important opportunity was lost in . . .